CBLL
Ceribell, Inc.
Next earnings Aug 3, 2026 · consensus $-0.48 EPS, $27.8M rev
Last earnings -19.3% on 2026-05-11
$19.98
▲ +1.27%$19.98▲ +5.71%
over 1Y
L $10.92EODHDH $23.33
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+1.3%
1M+6.8%
3M+12.4%
YTD-6.2%
1Y+5.7%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 14 analysts
Strong Buy
High-growth point-of-care EEG with 88% gross margins and a fresh FDA delirium clearance — speculative but compelling at 8x sales.
Revenue $89.1M · FY2025
Ceribell is executing a classic land-and-expand in acute-care EEG, with revenue compounding from $45.2M to $89.1M over two years (36.1% YoY in FY2025) and an 87.9% gross margin that screams platform/software-like unit economics. The MD&A confirms the Ceribell System has been adopted by 'more than 600 hospitals' out of an addressable ~6,000 U.S. acute care facilities — roughly 10% penetration with 90% of the TAM still ahead, supported by an expanding direct U.S. sales force and a CE Mark for Europe.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $45.2M | $65.4M | $89.1M |
| Gross profit | $38.2M | $56.8M | $78.3M |
| Operating income | -$30.0M | -$39.7M | -$58.4M |
| Net income | -$29.5M | -$40.5M | -$53.4M |
| Diluted EPS | -$5.56 | -$3.39 | -$1.46 |
| Net margin | -65.1% | -61.8% | -60.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$712M
EV / EBITDA—
EV / Sales8.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.1%
FCF yield-5.5%
Quality & risk
ROIC (est.)-29.7%
Free cash flow-$41.6M
Total debt—
Net cash$40.5M
Altman Z-Score10.07 safe
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-15open ↗144Filing2026-06-11open ↗4Period ending 2026-06-082026-06-10open ↗144Filing2026-06-08open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗8-KPeriod ending 2026-06-022026-06-02open ↗4Period ending 2026-03-102026-05-26open ↗
Frequently asked
- Is Ceribell, Inc. (CBLL) a buy?
- CBLL currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. High-growth point-of-care EEG with 88% gross margins and a fresh FDA delirium clearance — speculative but compelling at 8x sales.
- What is Ceribell, Inc.'s quality score?
- CBLL scores 44.29411764705882/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001861107, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/25/2026, 3:20:23 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.